[
  {
    "info": {
      "NCT": "NCT04613596",
      "Protocol_No": "849-007",
      "jit": "Tempus",
      "trial_name": "Mirati KRYSTAL-7 (849-007) "
    },
    "disease": {
      "summary": "Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer",
      "details": [
        {
          "code": "Non-Small Cell Lung Cancer (NSCLC)",
          "selection": "include"
        }
      ]
    },
    "query": {
      "nct": "NCT04613596",
      "title": "Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7",
      "current_status": "Recruiting",
      "status_verif_date": "September 2022",
      "last_update_date": "September 6, 2022",
      "trial_hold_status": "open",
      "sponsor": "Mirati Therapeutics Inc.",
      "brief_summary": "This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.",
      "conditions": "Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Cohort 1a: PD-L1 TPS <1%",
          "drug": "MRTX849 in Combination with Pembrolizumab",
          "arm_type": "Experimental",
          "line_of_therapy": "1",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Cohort 1a: PD-L1 TPS <1%",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "PD-L1",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "low",
              "summary": "PD-L1 TPS <1% low  "
            },
            {
              "cohort": "Cohort 1a: PD-L1 TPS <1%",
              "Gene": "KRAS",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "G12C",
              "Selection": "include",
              "Function": "Not available",
              "summary": "KRAS G12C Mutation  "
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Cohort 1b: PD-L1 TPS <1%",
          "drug": "MRTX849 Monotherapy",
          "arm_type": "Experimental",
          "line_of_therapy": "1",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Cohort 1b: PD-L1 TPS <1%",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "PD-L1",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "low",
              "summary": "PD-L1 TPS <1% low  "
            },
            {
              "cohort": "Cohort 1b: PD-L1 TPS <1%",
              "Gene": "KRAS",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "G12C",
              "Selection": "include",
              "Function": "Not available",
              "summary": "KRAS G12C Mutation  "
            }
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "Cohort 2: PD-L1 TPS ≥1%",
          "drug": "MRTX849 in Combination with Pembrolizumab",
          "arm_type": "Experimental",
          "line_of_therapy": "1",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Cohort 2: PD-L1 TPS ≥1%",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "PD-L1",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "high",
              "summary": "PD-L1 TPS ≥1 high  "
            },
            {
              "cohort": "Cohort 2: PD-L1 TPS ≥1%",
              "Gene": "KRAS",
              "Gene2": "Not available",
              "Type": "Mutation",
              "Variant": "G12C",
              "Selection": "include",
              "Function": "Not available",
              "summary": "KRAS G12C Mutation  "
            }
          ]
        }
      ],
      "docs": "Q:\\MCK\\MOA\\Precision Oncology\\JIT Trials \\Tempus JIT_2022-09-06.docx ",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT04613596\" target=\"_blank\">NCT04613596<\/a>"
    }
  }
]
